Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.

× No keyword cloud information.

14 in total

1. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin.

Authors: Sarah L Ondrejka; Armin G Jegalian; Annette S Kim; Devon S Chabot-Richards; Jennifer Giltnane; David R Czuchlewski; Shashirekha Shetty; Mikkael A Sekeres; Ashwini Yenamandra; David Head; Madan Jagasia; Eric D Hsi
Journal: Haematologica Date: 2014-06-20 Impact factor: 9.941

2. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.

Authors: M Jawhar; N Naumann; M Knut; J Score; M Ghazzawi; B Schneider; K-A Kreuzer; M Hallek; H G Drexler; J Chacko; L Wallis; A Fabarius; G Metzgeroth; W-K Hofmann; A Chase; W Tapper; A Reiter; N C P Cross
Journal: Leukemia Date: 2017-07-28 Impact factor: 11.528

3. Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.

Authors: Yoshimitsu Shimomura; Hayato Maruoka; Takayuki Ishikawa
Journal: Int J Hematol Date: 2016-12-20 Impact factor: 2.490

4. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.

Authors: Georgia Metzgeroth; Juliana Schwaab; Nicole Naumann; Mohamad Jawhar; Torsten Haferlach; Alice Fabarius; Andreas Hochhaus; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal: Blood Adv Date: 2020-02-11

5. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway.

Authors: P P Piccaluga; M Rossi; C Agostinelli; F Ricci; A Gazzola; S Righi; F Fuligni; M A Laginestra; M Mancini; M R Sapienza; A De Renzo; P L Tazzari; D Gibellini; P Went; F Alviano; P L Zinzani; G P Bagnara; G Inghirami; C Tripodo; S A Pileri
Journal: Leukemia Date: 2014-01-31 Impact factor: 11.528

6. F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.

Authors: S P Gorantla; K Zirlik; A Reiter; C Yu; A L Illert; N Von Bubnoff; J Duyster
Journal: Leukemia Date: 2015-03-12 Impact factor: 11.528

Review 7. Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.

Authors: Rory M Shallis; Alexa J Siddon; Amer M Zeidan
Journal: Curr Hematol Malig Rep Date: 2021-04-22 Impact factor: 3.952

Review 8. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.

Authors: Anna M Eiring; Michael W Deininger
Journal: Genome Biol Date: 2014-09-17 Impact factor: 13.583

Review 9. Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Authors: Peter Valent; Cem Akin; Michel Arock; Christoph Bock; Tracy I George; Stephen J Galli; Jason Gotlib; Torsten Haferlach; Gregor Hoermann; Olivier Hermine; Ulrich Jäger; Lukas Kenner; Hans Kreipe; Ravindra Majeti; Dean D Metcalfe; Alberto Orfao; Andreas Reiter; Wolfgang R Sperr; Philipp B Staber; Karl Sotlar; Charles Schiffer; Giulio Superti-Furga; Hans-Peter Horny
Journal: EBioMedicine Date: 2017-11-26 Impact factor: 8.143

10. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.

Authors: Yanli Jin; Ke Ding; Honglin Li; Mengzhu Xue; Xiaoke Shi; Chengyan Wang; Jingxuan Pan
Journal: Mol Cancer Date: 2014-01-28 Impact factor: 27.401